<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353467</url>
  </required_header>
  <id_info>
    <org_study_id>2017-FXY-055-NPC</org_study_id>
    <nct_id>NCT03353467</nct_id>
  </id_info>
  <brief_title>Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>A Prospective Clinical Trial of Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma (NPC) is most prevalent in eastern Asia, with the highest incidence&#xD;
      reported among the Cantonese population from the province of Guangdong. Radiotherapy is the&#xD;
      cornerstone of initial treatment due to the radiosensitive behavior of NPC and its&#xD;
      deep-seated location. Although radiotherapy has achieved satisfactory results, it can also&#xD;
      cause some severe adverse events. Currently, surgery is only applied to the treatment of&#xD;
      recurrent NPC (rNPC) patients, mainly dominated by the conventional open surgery. However,&#xD;
      the traditional surgery was accompanied by high rate of treatment-induced complications and&#xD;
      low rate of block removal, which greatly limited the surgical application to the treatment of&#xD;
      primary NPC.&#xD;
&#xD;
      With the continuous improvement in surgical techniques, especially the electronic endoscopic&#xD;
      system to be used in the surgical treatment recently, endoscopic nasopharyngectomy can&#xD;
      largely overcome these shortcomings of traditional surgery mentioned above.&#xD;
&#xD;
      In addition, the investigators retrospectively analyzed the survival outcomes of 9 patients&#xD;
      with NPC (all T1N0M0 according to the UICC / AJCC seventh staging) treated with endoscopic&#xD;
      nasopharyngectomy in our hospital, with 5-year rate of overall survival, loco-regional-free&#xD;
      survival, distant metastasis-free survival of 100%. Therefore, the investigators considered&#xD;
      endoscopic nasopharyngectomy for staged I NPC patients feasible.&#xD;
&#xD;
      This study will focus on the survival outcomes and quality of life of the staged I NPC&#xD;
      patients treated with endoscopic nasopharyngectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>The event for overall survival (OS) was death from any cause. The duration was calculated from the date of treatment initiation to the date of death or last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The event for distant metastasis-free survival (DMFS) was distant metastasis. The duration was calculated from the date of treatment initiation to the date of distant metastasis or the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>loco-regional relapse-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The event for loco-regional relapse-free survival (LRRFS) was loco-regional recurrence. The duration was calculated from the date of treatment initiation to the date of loco-regional relapse or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rates of complications</measure>
    <time_frame>1 year</time_frame>
    <description>These complications included mucositis, pharyngitis, xerostomia, nasopharyngeal necrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Endoscopic Surgery</condition>
  <condition>Primary Napharyngeal Carcinama</condition>
  <condition>Stage I Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Group in endoscopic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group in IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic surgery</intervention_name>
    <description>Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.</description>
    <arm_group_label>Group in endoscopic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.</description>
    <arm_group_label>Group in IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated, biopsy-proven World Health Organization (WHO) types II or III&#xD;
             NPC; Stage I disease (American Joint Committee on Cancer 7th edition); Between 18 and&#xD;
             70 years old; Adequate bone marrow, liver and renal function; Satisfactory performance&#xD;
             status: a score of 0 or 1 using the Eastern Cooperative Oncology Group System;&#xD;
             Patients provided signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of relapse or distant metastasis; History of prior malignancy or previous&#xD;
             treatment for NPC; The presence of uncontrolled life-threatening diseases; The&#xD;
             investigator considered the patient unable to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD,Ph.D</last_name>
    <phone>86-13903052650</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, Prof.</last_name>
      <phone>86-20-8734-3361</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Yuan Chen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiong Zou, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui You, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Ping Wen, MD, PhD</last_name>
      <phone>86-13802966937</phone>
      <email>wenwp@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Tang, MD</last_name>
      <phone>86-18038860199</phone>
      <email>tjun@fsyyy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Lei</last_name>
      <phone>86-13528227676</phone>
      <email>13528227676@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ming-Fang Ji</last_name>
      <phone>86-13532062222</phone>
      <email>jmftbh@aliyun.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen-Hong Qu, MD, PhD</last_name>
      <phone>86-15807813816</phone>
      <email>qshdoctor@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

